Found:
10 trials shown from 1163 total

Biomarkers in Samples From Patients With Endometrial Cancer

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn mor

Study number:
NCT01199250
Cohorts:
1
Study phase:
N/A
Overall status:
Not yet recruiting
Study type:
Observational, Biomarker

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who r

Study number:
NCT05920356
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Chemotherapy, Targeted therapy

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Loca

Study number:
NCT05801029
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Study number:
NCT05883644
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Immunotherapy

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulv

Study number:
NCT05646862
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Targeted therapy, Hormonal therapy

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Study number:
NCT05740566
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Chemotherapy

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow

Study number:
NCT05840211
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Chemotherapy, Hormonal therapy

A Study of EBC-129 in Advanced Solid Tumours

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Study number:
NCT05701527
Cohorts:
1
Study phase:
1
Overall status:
Recruiting
Study type:
Any

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lu

Study number:
NCT05462873
Cohorts:
1
Study phase:
1
Overall status:
Recruiting
Study type:
Any

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficac

Study number:
NCT05516628
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Local/Regional therapies, Immunotherapy